For Better or Worse: FFAR1 and FFAR4 Signaling in Cancer and Diabetes
Author(s) -
Julia M. Houthuijzen
Publication year - 2016
Publication title -
molecular pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.469
H-Index - 198
eISSN - 1521-0111
pISSN - 0026-895X
DOI - 10.1124/mol.116.105932
Subject(s) - free fatty acid receptor 1 , diabetes mellitus , cancer , receptor , gpr120 , fatty acid , endocrinology , cancer research , chemistry , medicine , microbiology and biotechnology , biology , biochemistry , g protein coupled receptor , agonist
Increased energy intake can lead to obesity, which increases the risk for the development of diabetes and cancer. Free fatty acids regulate numerous cellular processes, like insulin secretion, inflammation, proliferation, and cell migration. Dysregulation of these cellular functions by increased lipid intake plays a significant role in the development of diseases like diabetes and cancer. Free fatty acid receptors 1 and 4 (FFAR1 and FFAR4) are two free fatty acid receptors under increasing investigation for their roles in diabetes and more recently also cancer. Both receptors bind medium- to long-chain, saturated and omega-3 unsaturated fatty acids. Increasing evidence shows that enhanced FFAR1 and FFAR4 signaling reduces diabetes symptoms but enhances tumor growth and migration of various cancer types like melanoma and prostate cancer. This review gives an overview of the role of FFAR1 and FFAR4 in diabetes and cancer and discusses their potential to function as targets for treatment.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom